PRESIDENT HAS SERVED AS A REVIEWER FOR THE BST-F (80) BIOENGINEERING ‘ACADEMIC RESEARCH ENHANCEMENT AWARD’ STUDY SECTION FOR THE NIH
PDX Pharma’s President has served as a reviewer for the BST-F (80) Bioengineering ‘Academic Research Enhancement Award’ Study Section for the National Institute of Health (NIH) held on March 9, 2017.
pdx news
PDX Pharma awarded two-year $1.87M phase II SBIR grant from the National Cancer Institute (NCI) for the development of ARAC-02, a novel lung cancer treatment